

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Ublituximab for treating relapsing-remitting multiple sclerosis ID6350

Provisional Stakeholder List

Consultees	Commentators (no right to submit or
	appeal)
Company	<u>General</u>
Neuraxpharm UK (ublituximab)	All Wales Therapeutics and Toxicology
Detient/serer groups	Centre
Patient/carer groupsBrain and Spine Foundation	Allied Health Professionals Federation Poord of Community Health Councils in
Brain Charity	 Board of Community Health Councils in Wales
MS-UK	British National Formulary
Multiple Sclerosis National	Care Quality Commission
Therapy Centres	Department of Health, Social Services
Multiple Sclerosis Society	and Public Safety for Northern Ireland
Multiple Sclerosis Trust	Healthcare Improvement Scotland
Neurological Alliance	Medicines and Healthcare products
Shift.ms Shift.ms	Regulatory Agency
South Asian Health Foundation Specialized Health save	Multiple Sclerosis Society Wales Netional Association of Primary Care
 Specialised Healthcare Alliance 	National Association of Primary CareNational Pharmacy Association
Alliance	Neurological Alliance of Scotland
Healthcare professional groups	NHS Confederation
Association of British	Scottish Medicines Consortium
Neurologists	Wales Neurological Alliance
 British Association of 	Welsh Government
Neuroscience Nurses	Welsh Health Specialised Services
British Geriatrics Society	Committee
British Neuropathological	
Society	Possible comparator companies
 British Society for Blood and Marrow Transplantation 	Almirall Limited (dimethyl fumarate)
British Society of Rehabilitation	Amarox Limited (fingolimod) Attached Discussional HK Ltd (clouds in a)
Medicine	Atnahs Pharma UK Ltd (cladribine) Atnahs Pharma Crab L (torifly partide)
Chartered Society of	axunio Pharma GmbH (teriflunomide)Bayer plc (beta interferon)
Physiotherapy	Bayer pic (beta interferon)Biocon Pharma UK Limited (fingolimod)
Institute of Neurology	Biogen Idec Ltd (beta interferon,
London MS-AHSCT	peginterferon beta-1a, dimethyl
Collaborative Group	fumarate, diroximel fumarate,
 National Neurosciences 	natalizumab)
Advisory Group	,


Provisional stakeholder list for the evaluation of ublituximab for treating relapsing–remitting multiple sclerosis ID6350



Consultees Commentators (no right to submit or appeal) Dr. Reddy's Laboratories (UK) Ltd **Primary Care and Community Neurology Society** (fingolimod) Royal College of General Flynn Pharma Ltd (fingolimod) **Practitioners** Glenmark Pharmaceuticals Europe Ltd Royal College of Nursing (fingolimod) Royal College of Occupational Janssen-Cilag Ltd (ponesimod) **Therapists** LIPOMED GmbH (cladribine) Royal College of Pathologists Merck (beta interferon, cladribine) Royal College of Physicians Mylan (glatiramer acetate, teriflunomide, Royal Pharmaceutical Society fingolimod) Royal Society of Medicine Novartis Pharmaceuticals UK Ltd (beta Therapists in MS interferon, ofatumumab, fingolimod) Ranbaxy (UK) Limited a Sun **UK Clinical Pharmacy** Pharmaceutical Company (fingolimod) Association Roche Products Limited (ocrelizumab) **UK Multiple Sclerosis Specialist Nurse Association** Sandoz Limited (fingolimod) Sanofi Genzyme (teriflunomide, <u>Others</u> alemtuzumab) Department of Health and Teva Pharma B.V. (glatiramer acetate) Social Care Teva Pharmaceuticals Ltd (glatiramer NHS England acetate, fingolimod) Tillomed Laboratories Ltd (fingolimod) Zentiva (fingolimod) Relevant research groups Brain Research UK Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group Cochrane UK Genomics England MRC Clinical Trials Unit National Institute for Health Research Associated Public Health groups **Public Health Wales** UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Provisional stakeholder list for the evaluation of ublituximab for treating relapsing–remitting multiple sclerosis ID6350



Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.